Research programme: hypertension therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: hypertension therapeutics - Bristol-Myers Squibb

Alternative Names: BMS-346567; BMS-465149; BMS-509701

Latest Information Update: 21 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Isoxazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 03 Oct 2006 Data presented at the 232nd National Meeting of the American Chemical Society (232nd-ACS-2006) have been added to the pharmacokinetics and Hypertension pharmacodynamics sections
  • 04 Apr 2003 Preclinical trials in Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top